LOS ANGELES, February 17, 2016 - Stroke patients whose symptoms quickly improved before hospital arrival did not always have better recoveries than other patients, according to research presented at the American Stroke Association's International Stroke Conference 2016.
"Patients with very early rapid neurological improvement when first examined at the hospital still need to be considered for therapy to dissolve blood clots, given the high rate of unfavorable outcome," said Clotilde Balucani, M.D., Ph.D., lead author and research assistant professor in neurology at The State University of New York Downstate Medical Center in Brooklyn.
Since few studies have examined how rapid improvement of stroke symptoms might relate to recovery, the current study sought to clarify this possible relationship. Researchers found that stroke patients whose symptoms rapidly improved before hospital arrival were more likely to be discharged home, but a significant percentage -- one-third to nearly half -- were not. Although data analysis continues, patients who did not return home may have gone to long-term care facilities such as nursing homes or rehabilitation centers, researchers said.
Overall, almost 1 in 5 patients exhibited rapid improvement of symptoms. Compared to patients whose symptoms did not quickly resolve, these patients also were less likely to have high blood pressure and diabetes.
"To the extent that the data show a significant percent of patients with rapid neurological improvement do not have a good outcome, clinicians should strongly consider giving these patients intravenous medication to dissolve blood clots," Balucani said.
Researchers analyzed data from a large clinical study of 1,700 patients. They used a standard rating scale to measure stroke symptoms, including facial droop, hand grip, and arm strength. The patients' average age was about 70 years, most were white, and nearly half were female. More than three-fourths had high blood pressure.
Since the study included patients with symptoms caused by conditions other than clot-caused stroke, researchers plan to test the current findings by analyzing only patients diagnosed with this type of stroke.
Stroke is the fifth-leading cause of death in the United States and a leading cause of disability. During a stroke, a blood vessel to the brain either becomes blocked or bursts, preventing blood and oxygen from reaching the brain. Immediate treatment to restore blood flow is critical, so it is important to recognize the symptoms of stroke: face drooping, arm weakness, speech difficulty, time to call 9-1-1 (F.A.S.T.). Fortunately, most strokes are preventable by controlling risks, including high blood pressure, cigarette smoking, physical inactivity and heart disease.
Co-authors are Steven R Levine, M.D.; Nerses Sanossian, M.D.; Sidney Starkman, M.D.; David S. Liebeskind, M.D.; Samuel Stratton, M.D., M.P.H.; Marc Eckstein, M.D.; Scott Hamilton, Ph.D.; Robin Conwit, M.D.; and Jeffrey L. Saver, M.D. Author disclosures are on the abstract.
The original clinical study (Field Administration of Stroke Therapy - Magnesium Trial) was funded by the National Institutes of Health, National Institute for Neurological Disorders and Stroke.
Any available downloadable video/audio interviews, B-roll, animation, graphic, and images related to this news release are on the right column of the release link http://newsroom.
Video clips with researchers/authors of the studies will be added to the release link as available.
Follow news from ASA's International Stroke Conference 2016 via Twitter @HeartNews #ISC16.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.